Xin Lang Cai Jing·2025-10-09 01:56Group 1 - The core point of the news is that Nocera Biopharma's stock price dropped by 5.33% to 27.00 CNY per share, with a trading volume of 305 million CNY and a turnover rate of 3.99%, resulting in a total market capitalization of 47.645 billion CNY [1] - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Group 2 - Dongzheng Asset Management has a fund that heavily invests in Nocera Biopharma, with the "Oriental Red Medical Upgrade Stock Initiation A" fund reducing its holdings by 865,300 shares, now holding 2.6276 million shares, which represents 4.55% of the fund's net value [2] - The fund has experienced a floating loss of approximately 3.9939 million CNY due to the reduction in holdings [2] - The "Oriental Red Medical Upgrade Stock Initiation A" fund was established on March 29, 2022, with a current size of 481 million CNY, achieving a year-to-date return of 76.91% and a one-year return of 67.24% [2]